BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 30446443)

  • 1. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy.
    Ecke TH; Stier K; Weickmann S; Zhao Z; Buckendahl L; Stephan C; Kilic E; Jung K
    Cancer Med; 2017 Oct; 6(10):2252-2262. PubMed ID: 28879675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    Yasui M; Kawahara T; Izumi K; Yao M; Ishiguro Y; Ishiguro H; Uemura H; Miyoshi Y
    BMC Cancer; 2019 Apr; 19(1):331. PubMed ID: 30961575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
    Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
    Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
    Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C
    Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
    Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
    Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer.
    Baumgart S; Meschkat P; Edelmann P; Heinzelmann J; Pryalukhin A; Bohle R; Heinzelbecker J; Stöckle M; Junker K
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2725-2736. PubMed ID: 31552489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
    Du L; Jiang X; Duan W; Wang R; Wang L; Zheng G; Yan K; Wang L; Li J; Zhang X; Pan H; Yang Y; Wang C
    Oncotarget; 2017 Jun; 8(25):40832-40842. PubMed ID: 28388561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer.
    Mitra AP; Lam LL; Ghadessi M; Erho N; Vergara IA; Alshalalfa M; Buerki C; Haddad Z; Sierocinski T; Triche TJ; Skinner EC; Davicioni E; Daneshmand S; Black PC
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25344601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence.
    Andrew AS; Marsit CJ; Schned AR; Seigne JD; Kelsey KT; Moore JH; Perreard L; Karagas MR; Sempere LF
    Int J Cancer; 2015 Sep; 137(5):1158-66. PubMed ID: 25556547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel nomograms to predict recurrence and progression in primary non-muscle-invasive bladder cancer: validation of predictive efficacy in comparison with European Organization of Research and Treatment of Cancer scoring system.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    World J Urol; 2019 Sep; 37(9):1867-1877. PubMed ID: 30535715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of reference genes for the detection of serum microRNAs by reverse transcription-quantitative polymerase chain reaction in patients with bladder cancer.
    Wang L; Liu Y; Du L; Li J; Jiang X; Zheng G; Qu A; Wang H; Wang L; Zhang X; Liu H; Pan H; Yang Y; Wang C
    Mol Med Rep; 2015 Jul; 12(1):615-22. PubMed ID: 25738263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
    Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma.
    Okumura T; Kojima H; Miwa T; Sekine S; Hashimoto I; Hojo S; Nagata T; Shimada Y
    World J Surg Oncol; 2016 Aug; 14(1):228. PubMed ID: 27565418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.